Anti-TNF-α Biotherapies: Perspectives for Evidence-Based Personalized Medicine

• Langford CA . Drug insight: anti-tumor necrosis factor therapies for the vasculitic diseases. Nat. Clin. Pract. Rheumatol.4 , 364–370 (2008).
   PubMedGoogle Scholar
• Emery P , FleischmannRM, MorelandLW et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 60 , 2272–2283 (2009).
   PubMed Web of Science ®Google Scholar
• Allez M , KarmirisK, LouisE et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects. J. Crohns Colitis 4 , 355–366 (2010).
   PubMed Web of Science ®Google Scholar
• Handa T , TsunekawaH, YonedaM et al. Long-term remission of ocular and extraocular manifestations in Behcet‘s disease using infliximab. Clin. Exp. Rheumatol. 29 , S58–S63 (2011).
   PubMed Web of Science ®Google Scholar
• Furst DE , KeystoneEC, BraunJ et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann. Rheum. Dis. 70(Suppl. 1) , I2–I36 (2011).
   PubMed Web of Science ®Google Scholar
• Oxholm A , OxholmP, StabergB, BendtzenK. Immunohistological detection of interleukin 1-like molecules and tumour necrosis factor in human epidermis before and after UVB-irradiation in vivo. Br. J. Dermatol.118 , 369–376 (1988).
   PubMed Web of Science ®Google Scholar
• Deleuran BW , ChuCQ, FieldM et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor α. Arthritis Rheum. 35 , 1170–1178 (1992).
   PubMed Web of Science ®Google Scholar
• Reinecker HC , SteffenM, WitthoeftT et al. Enhanced secretion of tumour necrosis factor-α, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn‘s disease. Clin. Exp. Immunol. 94 , 174–181 (1993).
   PubMed Web of Science ®Google Scholar
• Elliott MJ , MainiRN, FeldmannM et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 36 , 1681–1690 (1993).
   PubMed Web of Science ®Google Scholar
• Baert FJ , D‘HaensGR, PeetersM et al. Tumor necrosis factor a antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn‘s ileocolitis. Gastroenterology 116 , 22–28 (1999).
   PubMed Web of Science ®Google Scholar
• McDermott MF , AksentijevichI, GalonJ et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97 , 133–144 (1999).
   PubMed Web of Science ®Google Scholar
• Lobuglio AF , WheelerRH, TrangJ et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl Acad. Sci. USA 86 , 4220–4224 (1989).
   PubMed Web of Science ®Google Scholar
• van Dullemen HM , van Deventer SJH, Hommes DW et al. Treatment of Crohn‘s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology109 , 129–135 (1995).
   PubMed Web of Science ®Google Scholar
• Moreland LW , BaumgartnerSW, SchiffMH et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337 , 141–147 (1997).
   PubMed Web of Science ®Google Scholar
• Choy EH , HazlemanB, SmithM et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a Phase II double-blinded, randomized, dose-escalating trial. Rheumatology 41 , 1133–1137 (2002).
   PubMed Web of Science ®Google Scholar
• den Broeder A , van de Putte L, Rau R et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-α antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J. Rheumatol.29 , 2288–2298 (2002).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ . Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr. Gastroenterol. Rep.5 , 501–505 (2003).
   PubMedGoogle Scholar
• Zhou H , JangH, FleischmannRM et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritis. J. Clin. Pharmacol. 47 , 383–396 (2007).
   PubMed Web of Science ®Google Scholar
• Assasi N , BlackhouseG, XieF et al. Patient outcomes after anti TNF-α drugs for Crohn‘s disease. Expert Rev. Pharmacoecon. Outcomes Res. 10 , 163–175 (2010).
   PubMed Web of Science ®Google Scholar
• Bendtzen K . Immunogenicity of anti-TNF antibodies. In: Immunogenicity of Biopharmaceuticals (Volume VIII). van de Weert M, M⊘ller EH (Eds). Springer, NY, USA, 189–203 (2008).
   Google Scholar
• Strand V , KimberlyR, IsaacsJD. Biologic therapies in rheumatology: lessons learned, future directions. Nat. Rev. Drug Discov.6 , 75–92 (2007).
   PubMed Web of Science ®Google Scholar
• Bendtzen K , AinsworthM, SteenholdtC, ThomsenOO, BrynskovJ. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-α antibodies. Scand. J. Gastroenterol.44 , 774–781 (2009).
   PubMed Web of Science ®Google Scholar
• Krieckaert CL , BarteldsGM, LemsWF, WolbinkGJ. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res. Ther.12 , 217 (2010).
   PubMed Web of Science ®Google Scholar
• Bendtzen K , GeborekP, SvensonM, LarssonL, KapetanovicMC, SaxneT. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor Infliximab. Arthritis Rheum.54 , 3782–3789 (2006).
   PubMed Web of Science ®Google Scholar
• Ternant D , AubourgA, Magdelaine-BeuzelinC et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther. Drug Monit. 30 , 523–529 (2008).
   PubMed Web of Science ®Google Scholar
• Ainsworth MA , BendtzenK, BrynskovJ. Tumor necrosis factor-α binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn‘s disease. Am. J. Gastroenterol.103 , 944–948 (2008).
   PubMed Web of Science ®Google Scholar
• Wijbrandts CA , DijkgraafMG, KraanMC et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium. Ann. Rheum. Dis. 67 , 1139–1144 (2008).
   PubMed Web of Science ®Google Scholar
• Bendtzen K . Editorial: Is there a need for immunopharmacological guidance of anti-TNF therapies? Arthritis Rheum.63 , 867–870 (2011).
   PubMed Web of Science ®Google Scholar
• Emery P . Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology (Oxf.).51(Suppl. 5) , V22–V30 (2012).
   PubMed Web of Science ®Google Scholar
• Kromminga A , SchellekensH. Antibodies against erythropoietin and other protein-based therapeutics: an overview. Ann. N. Y. Acad. Sci.1050 , 257–265 (2005).
   PubMed Web of Science ®Google Scholar
• Shankar G , ShoresE, WagnerC, Mire-SluisA. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol.24 , 274–280 (2006).
   PubMed Web of Science ®Google Scholar
• Hartung HP , PolmanC, BertolottoA et al. Neutralising antibodies to interferon β in multiple sclerosis: Expert panel report. J. Neurol. 254 , 827–837 (2007).
   PubMed Web of Science ®Google Scholar
• Ehrenforth S , SeremetisS. Case study: Immunogenicity of factor VIII. In: Immunogenicity of Biopharmaceuticals (Volume VIII). van de Weert M, M⊘ller EH (Eds). Springer, NY, USA, 147–171 (2008).
   Google Scholar
• Tamilvanan S , RajaNL, SaB, BasuSK. Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body. J. Drug Target18 , 489–498 (2010).
   PubMed Web of Science ®Google Scholar
• Richard J , PrangN. The formulation and immunogenicity of therapeutic proteins: product quality as a key factor. IDrugs13 , 550–558 (2010).
   PubMedGoogle Scholar
• Nielsen CH , BendtzenK. Immunoregulation by naturally occurring and disease-associated autoantibodies: binding to cytokines and their role in regulation of T-cell responses. Adv. Exp. Med. Biol.750 , 116–132 (2012).
   PubMed Web of Science ®Google Scholar
• Fefferman DS , FarrellRJ. Immunogenicity of biological agents in inflammatory bowel disease. Inflamm. Bowel Dis.11 , 497–503 (2005).
   PubMed Web of Science ®Google Scholar
• Wolbink GJ , VisM, LemsW et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 54 , 711–715 (2006).
   PubMed Web of Science ®Google Scholar
• Bartelds GM , WijbrandtsCA, NurmohamedMT et al. Clinical response to adalimumab: The relationship with anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66 , 921–926 (2007).
   PubMed Web of Science ®Google Scholar
• Ebert EC , DasKM, MehtaV, RezacC. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-α antibodies. Clin. Exp. Immunol.154 , 325–331 (2008).
   PubMed Web of Science ®Google Scholar
• West RL , ZelinkovaZ, WolbinkGJ, KuipersEJ, StokkersPC, Van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn‘s disease. Aliment Pharmacol. Ther.28 , 1122–1126 (2008).
   PubMed Web of Science ®Google Scholar
• Ko JM , GottliebAB, KerbleskiJF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J. Dermatolog. Treat.20 , 100–108 (2009).
   PubMed Web of Science ®Google Scholar
• Petitpain N , GambierN, WahlD, Chary-ValckenaereI, LoeuilleD, GilletP. Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000–2006. Biomed. Mater. Eng.19 , 355–364 (2009).
   PubMed Web of Science ®Google Scholar
• Cassinotti A , TravisS. Incidence and clinical significance of immunogenicity to infliximab in Crohn‘s disease: a critical systematic review. Inflamm. Bowel Dis.15 , 1264–1275 (2009).
   PubMed Web of Science ®Google Scholar
• Wolbink GJ , AardenLA, DijkmansBA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr. Opin. Rheumatol.21 , 211–215 (2009).
   PubMed Web of Science ®Google Scholar
• Karmiris K , PaintaudG, NomanM et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn‘s disease. Gastroenterology 137 , 1628–1640 (2009).
   PubMed Web of Science ®Google Scholar
• Aikawa NE , JF de Carvalho, Silva CA, Bonfa E. Immunogenicity of anti-TNF-α agents in autoimmune diseases. Clin. Rev. Allergy Immunol.38 , 82–89 (2010).
   PubMed Web of Science ®Google Scholar
• Jamnitski A , BarteldsGM, NurmohamedMT et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann. Rheum. Dis. 70 , 284–288 (2010).
   PubMed Web of Science ®Google Scholar
• Lecluse LL , DriessenRJ, SpulsPI et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch. Dermatol. 146 , 127–132 (2010).
   PubMed Web of Science ®Google Scholar
• Makol A , GroverM, GuggenheimC, HassounaH. Etanercept and venous thromboembolism: a case series. J. Med. Case Reports4 , 12 (2010).
   PubMedGoogle Scholar
• Bartelds GM , KrieckaertCL, NurmohamedMT et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305 , 1460–1468 (2011).
   PubMed Web of Science ®Google Scholar
• Korswagen LA , BarteldsGM, KrieckaertCL et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum. 63 , 877–883 (2011).
   PubMed Web of Science ®Google Scholar
• Steenholdt C , SvensonM, BendtzenK, ThomsenO, BrynskovJ, AinsworthMA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol. Ther.34 , 51–58 (2011).
   PubMed Web of Science ®Google Scholar
• Yanai H , HanauerSB. Assessing response and loss of response to biological therapies in IBD. Am. J. Gastroenterol.106 , 685–698 (2011).
   PubMed Web of Science ®Google Scholar
• Steenholdt C , SvensonM, BendtzenK, ThomsenO, BrynskovJ, AinsworthMA. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn‘s disease. J. Crohns Colitis6 , 108–111 (2012).
   PubMed Web of Science ®Google Scholar
• Aarden L , RuulsSR, WolbinkG. Immunogenicity of anti-tumor necrosis factor antibodies – toward improved methods of anti-antibody measurement. Curr. Opin. Immunol.20 , 431–435 (2008).
   PubMed Web of Science ®Google Scholar
• Wolbink GJ , VoskuylAE, LemsWF et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64 , 704–707 (2005).
   PubMed Web of Science ®Google Scholar
• Descotes J , GouraudA. Clinical immunotoxicity of therapeutic proteins. Expert Opin. Drug Metab. Toxicol.4 , 1537–1549 (2008).
   PubMed Web of Science ®Google Scholar
• Dubey S , KerriganN, MillsK, ScottDG. Bronchospasm associated with anti-TNF treatment. Clin. Rheumatol.28 , 989–992 (2009).
   PubMed Web of Science ®Google Scholar
• Tangri S , MotheBR, EisenbraunJ et al. Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. 174 , 3187–3196 (2005).
   PubMed Web of Science ®Google Scholar
• Hwang WY , FooteJ. Immunogenicity of engineered antibodies. Methods36 , 3–10 (2005).
   PubMed Web of Science ®Google Scholar
• Cheifetz A , MayerL. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J. Med.72 , 250–256 (2005).
   PubMed Web of Science ®Google Scholar
• De Groot AS , ScottDW. Immunogenicity of protein therapeutics. Trends Immunol.28 , 482–490 (2007).
   PubMed Web of Science ®Google Scholar
• Radstake TR , SvensonM, EijsboutsAM et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann. Rheum. Dis. 68 , 1739–1745 (2009).
   PubMed Web of Science ®Google Scholar
• Afif W , LoftusEVJ, FaubionWA et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am. J. Gastroenterol. 105 , 1133–1139 (2010).
   PubMed Web of Science ®Google Scholar
• Jamnitski A , KrieckaertCL, NurmohamedMT et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann. Rheum. Dis. 71(1) , 88–91 (2012).
   PubMed Web of Science ®Google Scholar
• Ginsburg GS , McCarthyJJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol.19 , 491–496 (2001).
   PubMed Web of Science ®Google Scholar
• Maini RN , BreedveldFC, KaldenJR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41 , 1552–1563 (1998).
   PubMed Web of Science ®Google Scholar
• Candon S , MoscaA, RuemmeleF, GouletO, ChatenoudL, CezardJP. Clinical and biological consequences of immunization to infliximab in pediatric Crohn‘s disease. Clin. Immunol.118 , 11–19 (2006).
   PubMed Web of Science ®Google Scholar
• Steenholdt C , Al-khalafM, BrynskovJ, BendtzenK, ThomsenO, AinsworthMA. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm. Bowel Dis. doi:10.1002/ibd.22910 (2012) (Epub ahead of print).
   Google Scholar
• Vermeire S , NomanM, Van Assche G, Baert F, D‘Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn‘s disease. Gut56 , 1226–1231 (2007).
   PubMed Web of Science ®Google Scholar
• McDonald TA , ZepedaML, TomlinsonMJ, BeeWH, IvensIA. Subcutaneous administration of biotherapeutics: current experience in animal models. Curr. Opin. Mol. Ther.12 , 461–470 (2010).
   PubMedGoogle Scholar
• Hart MH , de Vrieze H, Wouters D et al. Differential effect of drug interference in immunogenicity assays. J. Immunol. Methods372 , 196–203 (2011).
   PubMed Web of Science ®Google Scholar
• Bendtzen K , SvensonM. Enzyme immunoassays and radioimmunoassays for quantification of anti-TNF biopharmaceuticals and anti-drug antibodies. In: Detection and Quantification of Antibodies to Biopharmaceuticals. Practical and Applied Considerations. Tovey MG (Ed.). John Wiley & Sons, West Sussex, UK, 83–101 (2011).
   Google Scholar
• Steenholdt C , BendtzenK, BrynskovJ, ThomsenOO, AinsworthMA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn‘s disease. Scand. J. Gastroenterol.46 , 310–318 (2011).
   PubMed Web of Science ®Google Scholar
• Svenson M , GeborekP, SaxneT, BendtzenK. Monitoring patients treated with anti-TNF-α biopharmaceuticals – assessing serum infliximab and anti-infliximab antibodies. Rheumatology46 , 1828–1834 (2007).
   PubMed Web of Science ®Google Scholar
• van Schouwenburg PA , BarteldsGM, HartMH, AardenL, WolbinkGJ, WoutersD. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals ‘hidden‘ immunogenicity in rheumatoid arthritis patients. J. Immunol. Methods362 , 82–88 (2010).
   PubMed Web of Science ®Google Scholar
• Lallemand C , KavrochorianouA, SteenholdtC et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists. J. Immunol. Meth. 373 , 229–239 (2011).
   PubMed Web of Science ®Google Scholar
• Cada DJ , LevienTL, BakerDE. Golimumab. Hosp. Pharm.44 , 894–907 (2009).
   Google Scholar

▪ Website

• European Medicines Agency (EMEA). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins 1–18 (2007) (www.ema.europa.eu/docs/en_gb/document_library/scientific_guideline/2009/09/wc500003946.pdf).
   Google Scholar